The Marzetti clears the business-activity screen and the figures we can measure look clean, but one or more financial figures are still pending, so the verdict is not final yet.
The Marzetti Company
MZTI · Nasdaq · USD · Market cap $3.1B · 3,700 employees
The Marzetti Company engages in manufacturing and marketing of specialty food products for the retail and foodservice channels in the United States.
Not yet scoredPrice as of 13 Nov 2026Daily close, not a live quote
Screened 2026-11-13 · the tape above runs as of 06:12 UTC · two dates, stated on purpose · verdict and workings shown in full · never trimmed
Key facts today
- Price110.97 USD at the 13 Nov 2026 close
- Our value readUndervalued vs our fair value, as of 13 Nov 2026
- Our regime readMarkup, as of 15 Nov 2026
- Ethical screenNot yet scored
- OptionsOpen interest leans slightly to calls (put/call 0.93)
- Last reviewed13 Nov 2026 (3 days ago)
- Release timesRelease and earnings times on your chart: Event Guard Mentor
A summary of the dated readings below, not a live quote and not advice.
Our fair-value range: $94.47 to $157.46, base estimate $130.48 (screen dated 2026-11-13).
- Trend Markup
- Insiders no filings inside 60 days, left as found
- Positioning no disclosures inside 60 days, left as found
- Options put/call open interest 0.93, read 2026-11-15
- Ethical screen not yet scored
Our analytic regime reads on this name, dated and marked against the screened price. Small sample per name, and separate from the daily-framework accuracy on the Track Record page.
This name holds its markup label.
The Marzetti Company holds its Markup at $110.97. Elevated stress, defensive posture warranted, held for 11 days.
| Phase | Markup |
| Quantitative state | Elevated stress, defensive posture warranted, held for 11 days |
| Price at the screen | $110.97 |
| Valuation | 17.68 trailing · 15.57 forward price to earnings |
| Values screen | Not scored · score 70.0 |
| Beta | 0.33 |
Five Screens, Shown in Full
This security has not been fully scored against the values screen yet.
| Test | Figure | Limit | What it means | Status |
|---|---|---|---|---|
| Business activity | Permissible | Core business clean | Its core business isn't built on prohibited lines: no gambling, alcohol, tobacco, weapons, or interest-based lending. | Pass |
| Debt load | 4.36% | Below 33% | Interest-bearing debt is just 4.4% of its assets, well under the one-third ceiling: it does not run on borrowed money. | Pass |
| Interest-bearing cash | 0.00% | Below 33% | Cash held in interest-bearing accounts and securities is 0.0% of assets, under the one-third limit. | Pass |
| Receivables | 20.18% | Below 49% | Money owed to the company is 20.2% of assets, under the 49% limit. | Pass |
| Revenue purity | 0.00% | Below 5% | Only 0.0% of revenue comes from non-compliant sources, under the 5% line. | Pass |
Five checks adapted from AAOIFI screening standards: business activity plus four balance-sheet ratios. All five must pass for ethical clearance. Every figure is arithmetic on public accounts, not judgement.
The Ethical ReadThe Read, in Plain English
The Marzetti clears the business-activity screen and the figures we can measure look clean, but one or more financial figures are still pending, so the verdict is not final yet.
Read as at 2026-11-14. It updates when the underlying figures move, and past reads are kept below.
The Marzetti clears all five screens. Its business is in a permissible area, its interest-bearing debt is about 4%, inside the ~33% line, and almost none of its income is interest, so it passes.
Earlier reads, kept as written. The ethical profile is tracked over time, not overwritten.
What the Numbers Say It Is WorthThe Fair Value Range
Our analysis reads Undervalued vs our fair value, as of 13 Nov 2026: it trades at roughly a 15% discount to our $130.48 fair value.
How a fair value is estimated: discounted cash flow (DCF).
Fair value range in USD, drawn from the 2026-11-13 screen. The gold marker is the market price at the same screen. A 15.0% discount to the base estimate.
Third-party analyst targets: 5 covering, consensus Buy. The average target sits +22% from the screen price.
Reading the gap · Both our model and the analysts see meaningful upside from here.
Price History & ProjectionsWhere our models see it going: fair-value estimate $130.48, with a range of $94.47 to $157.46, dated to the 2026-11-13 screen.
Fair value and rating are our own model estimates; the Street's range reflects third-party analyst estimates. Analysis, not advice.
The Business, in Plain WordsFrozen garlic bread meets a flat sales line
Every supermarket run includes a pack of New York Bakery garlic bread or a similar Marzetti product that moves from factory to table without much fuss. The business sits in steady defensive categories where demand rarely collapses, yet revenue slipped 1 percent last year while profit margins held at 9 percent and return on equity reached 17 percent. At 14.8 times forward earnings the shares trade below our fair value of 141 dollars, and the ethical screen clears without issue.
We still pass. Unknown competitive protection and zero top-line growth leave little room for sustained outperformance, even with a 32 percent margin of safety and a buy-rated analyst median target of 160 dollars. Defensive food names can look inexpensive for long stretches when volume stays flat.
Currency moves, private-label pressure and shifting consumer tastes in frozen goods remain live risks that could compress the current multiple further. The low growth already signals limited pricing power in a crowded aisle. Analysis, not advice.
| Forward P/E | 15.6xreasonably valued |
| Trailing P/E | 17.7xreasonably valued |
| EPS, trailing | 6.34 |
| EPS, forward | 7.20 |
| Revenue growth | -2.4%revenue is shrinking |
| Profit margin | 9.1%thin but positive margins |
| Return on equity | 16.8%a solid return on shareholder capital |
| Dividend yield | 3.50% |
| Debt to equity | 0.19minimal debt: a conservative balance sheet |
| Current ratio | 1.53healthy short-term liquidity |
| Beta | 0.33barely tracks the market's swings |
| Short interest, float | 0.27% |
| 52-week range | 97.00 - 176.26 |
| Market cap | $3.1B |
| Employees | 3,700 |
Another profit measure, before interest, tax and non-cash costs: EBITDA.
The risks · The main risks here are ordinary market swings and the chance our fair-value read proves too optimistic.
Plain-English interpretation of our own screen data. Analysis, not advice.
Where & How to TradeMZTI trades on Nasdaq. As a listed security it is accessible through almost any international broker offering its home market. New to this, or investing from abroad? Our guide to accessing global markets covers brokers, currencies and the practical steps.
Every Entry, As Written
The analysis reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 0.7% since our last review. Ethical screening: not fully scored yet. The risk-adjusted return profile shows negative risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is sitting below its long-term trend line with momentum reading neutral. Over the past year the shares are down 34%. Our forward projection puts the odds of a 10% gain over the next month near 11%. The street (5 analysts) rates it none, with a mean price target of $159. Since the last review it its composite score rose.
The analysis reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 0.0% since our last review. Ethical screening: not fully scored yet. The risk-adjusted return profile shows negative risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is sitting below its long-term trend line with momentum reading overbought. Over the past year the shares are down 34%. Our forward projection puts the odds of a 10% gain over the next month near 11%. The street (5 analysts) rates it none, with a mean price target of $159. It reported earnings in this window, a natural checkpoint for the thesis.
The analysis reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 0.0% since our last review. Ethical screening: not fully scored yet. The risk-adjusted return profile shows negative risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is sitting below its long-term trend line with momentum reading overbought. Over the past year the shares are down 34%. Our forward projection puts the odds of a 10% gain over the next month near 11%. The street (5 analysts) rates it none, with a mean price target of $159. It reported earnings in this window, a natural checkpoint for the thesis.
The analysis reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved up 0.6% since our last review. Ethical screening: not fully scored yet. The risk-adjusted return profile shows negative risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is sitting below its long-term trend line with momentum reading overbought. Over the past year the shares are down 34%. Our forward projection puts the odds of a 10% gain over the next month near 11%. The street (5 analysts) rates it none, with a mean price target of $159. It reported earnings in this window, a natural checkpoint for the thesis.
The analysis reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 0.0% since our last review. Ethical screening: not fully scored yet. The risk-adjusted return profile shows negative risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is sitting below its long-term trend line with momentum reading overbought. Over the past year the shares are down 34%. Our forward projection puts the odds of a 10% gain over the next month near 11%. The street (5 analysts) rates it none, with a mean price target of $159. It reported earnings in this window, a natural checkpoint for the thesis.
The analysis reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 0.0% since our last review. Ethical screening: not fully scored yet. The risk-adjusted return profile shows negative risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is sitting below its long-term trend line with momentum reading overbought. Over the past year the shares are down 34%. Our forward projection puts the odds of a 10% gain over the next month near 11%. The street (5 analysts) rates it none, with a mean price target of $159. It reported earnings in this window, a natural checkpoint for the thesis.
The analysis reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved up 3.6% since our last review. Ethical screening: not fully scored yet. The risk-adjusted return profile shows negative risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is sitting below its long-term trend line with momentum reading overbought. Over the past year the shares are down 34%. Our forward projection puts the odds of a 10% gain over the next month near 11%. The street (5 analysts) rates it none, with a mean price target of $159. It reported earnings in this window, a natural checkpoint for the thesis.
The analysis reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 0.0% since our last review. Ethical screening: not fully scored yet. The risk-adjusted return profile shows negative risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is sitting below its long-term trend line with momentum reading overbought. Over the past year the shares are down 34%. Our forward projection puts the odds of a 10% gain over the next month near 11%. The street (5 analysts) rates it none, with a mean price target of $159. It reported earnings in this window, a natural checkpoint for the thesis.
The analysis reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 0.0% since our last review. Ethical screening: not fully scored yet. The risk-adjusted return profile shows negative risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is sitting below its long-term trend line with momentum reading overbought. Over the past year the shares are down 34%. Our forward projection puts the odds of a 10% gain over the next month near 11%. The street (5 analysts) rates it none, with a mean price target of $159. It reported earnings in this window, a natural checkpoint for the thesis.
The framework has shifted from accumulation to markup since the last review. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved up 2.1% since our last review. Ethical screening: not fully scored yet. The risk-adjusted return profile shows negative risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is sitting below its long-term trend line with momentum reading bullish. Over the past year the shares are down 34%. Our forward projection puts the odds of a 10% gain over the next month near 11%. The street (5 analysts) rates it none, with a mean price target of $159.
Each entry above was written on its date, before the outcome. A journal you can prune is not a journal.
- Has Marzetti (MZTI) Fallen Far Enough for Its Cash Flow Value? Yahoo Finance · 3d ago
- Marzetti (MZTI), What Is Behind The Fresh Attention Now? Yahoo Finance · 3d ago
- 4 stocks to combat Nvidia's concentration risk Yahoo Finance · 4d ago
- The Marzetti Company Increases Regular Cash Dividend; Elects Three Incumbent Directors Yahoo Finance · 4d ago
- ESAB's Middle East Footprint Could Win Rebuilding Demand Yahoo Finance · 5d ago
Headlines from third-party outlets, linked for reference: not our reporting, not advice.
Screened names in the same industry · explore each on its own page.
| Period | Price then | Price return | Divs per share | $1,000 became | Total return |
|---|---|---|---|---|---|
| 1 month | $111.24 | -1.2% | $1.00 | $997 | -0.3% |
| 2 months | $140.67 | -21.9% | $1.00 | $788 | -21.2% |
| 3 months | $150.52 | -27.0% | $1.00 | $737 | -26.3% |
| 6 months | $163.26 | -32.7% | $2.00 | $685 | -31.5% |
| 1 year | $165.87 | -33.7% | $3.95 | $686 | -31.4% |
| 2 years | $177.02 | -37.9% | $7.70 | $664 | -33.6% |
| 3 years | $185.38 | -40.7% | $11.25 | $653 | -34.7% |
| 5 years | $177.25 | -38.0% | $17.75 | $720 | -28.0% |
Historical returns from market close data. Past performance does not guarantee future results.
This entry now belongs to the ledger. Whatever MZTI does next, these words stay.
Thirteen thousand names carry this page. One desk keeps them honest.
Membership opens the full screen archive, the composites built from it, and the daily coverage that prices what the screen approves.
Join the deskScreening is research, not a fatwa and not financial advice. Figures are drawn from public accounts at the screen date shown. Always manage your risk.